Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Day One Biopharmaceuticals (DAWN) Income from Continuing Operations (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Income from Continuing Operations for 4 consecutive years, with 25287000.0 as the latest value for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 61.52% year-over-year to 25287000.0; the TTM value through Dec 2025 reached 111255000.0, up 45.64%, while the annual FY2025 figure was 111274000.0, 16.58% down from the prior year.
  • Income from Continuing Operations was 25287000.0 for Q4 2025 at Day One Biopharmaceuticals, down from 19692000.0 in the prior quarter.
  • The five-year high for Income from Continuing Operations was 35840000.0 in Q3 2024, with the low at 112397000.0 in Q2 2024.
  • Historically, Income from Continuing Operations has averaged 40435250.0 across 4 years, with a median of 38943500.0 in 2022.
  • The largest annual shift saw Income from Continuing Operations soared 177.66% in 2024 before it tumbled 154.94% in 2025.
  • Over 4 years, Income from Continuing Operations stood at 40083000.0 in 2022, then crashed by 35.95% to 54493000.0 in 2023, then fell by 20.58% to 65710000.0 in 2024, then skyrocketed by 61.52% to 25287000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 25287000.0 in Q4 2025, 19692000.0 in Q3 2025, and 30303000.0 in Q2 2025.